Metiphenal

Methylphenidate Hydrochloride, the active ingredient in Metiphenal, is a central nervous system stimulant presented as an oral formulation for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder and narcolepsy in appropriate patients.

GNH USA supplies Metiphenal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metiphenal is a central nervous system stimulant used in the management of specific neurobehavioral disorders.

- Attention deficit hyperactivity disorder (ADHD): improves focus, reduces hyperactivity and impulsivity. - Narcolepsy: decreases excessive daytime sleepiness and improves wakefulness. - Off‑label use is not listed; only the recognized indications are provided.

Adverse reactions may occur with methylphenidate therapy and are categorized by frequency.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced food intake leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach pain: abdominal discomfort or nausea. - Irritability: mood swings or increased agitation. - Increased heart rate: tachycardia or palpitations.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, arrhythmia, or myocardial infarction. - Psychosis: hallucinations or delusional thinking. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hallucinations: visual or auditory disturbances. - Priapism: prolonged painful erection. - Seizures: convulsive episodes.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for adverse outcomes.

- Cardiovascular assessment: check blood pressure and heart rate prior to treatment. - Psychiatric history: review for prior psychosis or severe anxiety. - Growth monitoring: assess weight and height in pediatric patients regularly. - Substance abuse: avoid use in individuals with a history of stimulant misuse. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Methylphenidate may interact with other agents, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase cardiovascular side effects. - Antihypertensive agents: can reduce blood pressure control.

Moderate Interactions (Monitor Closely):\n- CYP2D6 inhibitors (e.g., fluoxetine): may raise methylphenidate plasma levels. - Anticonvulsants (e.g., carbamazepine): may lower effectiveness. - Anticholinergic drugs: may exacerbate dry mouth and constipation.